Functional imaging of endocrine tumors: Role of positron emission tomography

Endocrine Reviews

Volumn 25, Issue 4, 2004, Pages 568-580

  Pacak, Karel ^a   Eisenhofer, Graeme ^b   Goldstein, David S ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 5 HYDROXYTRYPTOPHAN C 11; ADRENALIN C 11; AMMONIA N 13; ETOMIDATE C 11; FLUORODEOXYGLUCOSE F 18; FLUORODIHYDROXYPHENYLALANINE; FLUORODOPAMINE F 18; HYDROXYEPHEDRINE C 11; METHIONINE C 11; METHYLSPIPERONE C 11; PENTETREOTIDE IN 111; RACLOPRIDE C 11; RADIOISOTOPE; TECHNETIUM 99M; TYROSINE C 11; UNCLASSIFIED DRUG;

ADRENAL CORTEX TUMOR; CANCER DIAGNOSIS; CANCER LOCALIZATION; CARCINOID; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HYPOPHYSIS TUMOR; IMAGE ANALYSIS; IMAGING SYSTEM; METASTASIS; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SCINTISCANNING; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO; TECHNIQUE; THYROID CANCER; TUMOR GROWTH; ULTRASOUND;

ENDOCRINE GLAND NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 4143123664     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2003-0032     Document Type: Review

References (126)

1. Czernin J, Phelps ME 2002 Positron emission tomography scanning: current and future applications. Annu Rev Med 53:89-112
2. Bomanji JB, Costa DC, Ell PJ 2001 Clinical role of positron emission tomography in oncology. Lancet Oncol 2:157-164
3. Mankoff DA, Bellon JR 2001 Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin Radiat Oncol 11:16-27
4. Beyer T, Townsend DW, Blodgett TM 2002 Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 46:24-34
5. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME 2001 A tabulated summary of the FDG PET literature. J Nucl Med 42:1S-93S
6. Larson SM, Robbins R 2002 Positron emission tomography in thyroid cancer management. Semin Roentgenol 37:169-174
7. Cook GJ, Maisey MN, Fogelman I 1999 Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxy-glucose and carbon-11 methionine. Eur J Nucl Med 26:1363-1378
8. Shreve PD, Anzai Y, Wahl RL 1999 Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61-77
9. 18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 27:143-156
10. Vaalburg W, Coenen HH, Crouzel C, Elsinga PH, Langstrom B, Lemaire C, Meyer GJ 1992 Amino acids for the measurement of protein synthesis in vivo by PET. Int J Rad Appl Instrum B 19: 227-237
11. Willemsen AT, van Waarde A, Paans AM, Pruim J, Luurtsema G, Go KG, Vaalburg W 1995 In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-[1-11C]-tyrosine and PET. J Nucl Med 36:411-419
12. Lewis JS, Welch MJ 2001 PET imaging of hypoxia. Q J Nucl Med 45:183-188
13. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-1785
14. Blankenberg FG, Tait J, Ohtsuki K, Strauss HW 2000 Apoptosis: the importance of nuclear medicine. Nucl Med Commun 21:241-250
15. 18F]Fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38:6-8
16. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS 2001 Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315-329
17. Eriksson B, Bergström M, Orleförs H, Sundin A, Oberg K, Langström B 2000 Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 44:68-76
18. Muhr C, Bergström M 1991 Positron emission tomography applied in the study of pituitary adenomas. J Endocrinol Invest 14:509-528
19. Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, Maecke HR, Larson SM 2002 Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 29:147-157
20. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 28:1751-1757
21. Shagam JY 2001 Positron emission tomography. Radiol Technol 72:551-569; quiz 570-572
22. 131I whole-body scan. J Nucl Med 40:986-992
23. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F 2001 Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671-1676
24. 18F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234:804-811
25. Grünwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U, Biersack HJ 1999 Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26:1547-1552
26. 131I scan. J Nucl Med 42:71-76
27. Sisson JC, Ackermann RJ, Meyer MA, Wahl RL 1993 Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 77:1090-1094
28. 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291-2302
29. 18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107-1113
30. Yeo JS, Chung JK, So Y, Kim S, Lee E, Lee DS, Youn YK, Hong SJ, Ahn IM, Lee MC, Cho BY 2001 F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 23:94-103
31. 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 86:3779-3786
32. Robbins R, Drucker W, Hann L, Tuttle RM 2001 Advances in the detection of residual thyroid carcinoma. Adv Intern Med 46:277-294
33. Stokkel MP, de Klerk JH, Zelissen PM, Koppeschaar HP, van Rijk PP 1999 Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. Eur J Nucl Med 26:1606-1609
34. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W 1996 Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37:1468-1472
35. 131I scanning results after therapy. J Nucl Med 42:1464-1469
36. 35a. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P 2004 Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89:91-95
37. Ladenson PW, Ewertz ME, Dickey RA 2001 Practical application of recombinant thyrotropin testing in clinical practice. Endocr Pract 7:195-201
38. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM 2002 Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 87:3242-3247
39. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619-625
40. 131I scanning. J Clin Endocrinol Metab 87:1486-1489
41. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H 1997 Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24:1342-1348
42. Feine U 1998 Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer. Eur J Endocrinol 138:492-496
43. 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7:327-335
44. McDougall IR, Davidson J, Segall GM 2001 Positron emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 22:485-492
45. 18F-FDG PET. Eur J Nucl Med 29:231-236
46. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K, Hahn K 2000 Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41:1989-1995
47. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A 2000 The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 27:490-496
48. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66-71
49. Voth E, Borner AR, Theissen P, Schicha H 1994 Positron emission tomography (PET) in benign thyroid diseases. Exp Clin Endocrinol 102:71-74
50. Van den Bruel A, Maes A, De Potter T, Mortelmans L, Drijkoningen M, Van Damme B, Delaere P, Bouillon R 2002 Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 87:1517-1520
51. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B 1995 Incidentally discovered adrenal masses. Endocr Rev 16:460-484
52. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR 1998 Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 171:201-204
53. Dunnick NR, Korobkin M 2002 Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol 179:559-568
54. Korobkin M, Brodeur FJ, Yutzy GG, Francis IR, Quint LE, Dunnick NR, Kazerooni EA 1996 Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR Am J Roentgenol 166:531-536
55. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR, Raghupathi KI 2002 Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 222:629-633
56. Mitchell DG, Crovello M, Matteucci T, Petersen RO, Miettinen MM 1992 Benign adrenocortical masses: diagnosis with chemical shift MR imaging. Radiology 185:345-351
57. Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM, Mueller PR 1995 Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 194:131-134
58. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M 2001 The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med 42:884-892
59. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42:1795-1799
60. Dwamena BA, Kloos RT, Fendrick AM, Gross MD, Francis IR, Korobkin MT, Shapiro B 1998 Diagnostic evaluation of the adrenal incidentaloma: decision and cost-effectiveness analyses. J Nucl Med 39:707-712
61. Gross MD, Shapiro B, Francis IR, Glazer GM, Bree RL, Arcomano MA, Schteingart DE, McLeod MK, Sanfield JA, Thompson NW 1994 Scintigraphic evaluation of clinically silent adrenal masses. J Nucl Med 35:1145-1152
62. Lumachi F, Zucchetta P, Marzola MC, Bui F, Casarrubea G, Angelini F, Favia G 2002 Usefulness of CT scan, MRI and radiocholesterol scintigraphy for adrenal imaging in Cushing's syndrome. Nucl Med Commun 23:469-473
63. Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerstrom G, Langstrom B 2000 PET imaging of adrenal cortical tumors with the 11β-hydroxylase tracer 11C-metomidate. J Nucl Med 41:275-282
64. Bergström M, Bonasera TA, Lu L, Bergstrom E, Backlin C, Juhlin C, Langstrom B 1998 In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med 39:982-989
65. 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168:1357-1360
66. Ng L, Libertino JM 2003 Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169:5-11
67. Becherer A, Vierhapper H, Potzi C, Karanikas G, Kurtaran A, Schmaljohann J, Staudenherz A, Dudczak R, Kletter K 2001 FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 16: 289-295
68. 11C-Metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 30:403-410
69. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, Norton JA, Walther MM, Keiser HR, Neumann RD 1993 Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 34:173-179
70. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, Rosenspire KC, Shapiro B, Sisson JC, Kuhl DE 1992 PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. J Nucl Med 33:1125-1131
71. Shapiro B, Gross MD, Shulkin B 2001 Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 12:469-475
72. Eisenhofer G 2001 The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91:35-62
73. 131I]- metaiodobenzylguanidine scintigraphy. Int J Urol 6:119-124
74. 111In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685-693
75. 18F DOPA whole-body PET - initial results. Radiology 222:507-512
76. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC 1999 Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 212:35-41
77. Sisson JC, Shulkin BL 1999 Nuclear medicine imaging of pheochromocytoma and neuroblastoma. Q J Nucl Med 43:217-223
78. Shulkin BL, Shapiro B 1998 Current concepts on the diagnostic use of MIBG in children. J Nucl Med 39:679-688
79. Kushner BH, Yeung HW, Larson SM, Kramer K, Cheung NK 2001 Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 19:3397-3405
80. Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC 1996 Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2- deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199:743-750
81. Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG, Rawwas JB, Castle VP, Sisson JC, Hutchinson RJ 1996 PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 37:16-21
82. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK 1998 Carcinoid tumour. Lancet 352:799-805
83. Vincent JM, Trainer PJ, Reznek RH, Marcus AJ, Dacie JE, Armstrong P, Besser GM 1993 The radiological investigation of occult ectopic ACTH-dependent Cushing's syndrome. Clin Radiol 48:11-17
84. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB 2001 Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86:895-902
85. Nino-Murcia M, Jeffrey Jr RB 2002 Multidetector-row CT and volumetric imaging of pancreatic neoplasms. Gastroenterol Clin North Am 31:881-896
86. Shin HJ, Lahoti S, Sneige N 2002 Endoscopic ultrasound-guided fine-needle aspiration in 179 cases: the M.D. Anderson Cancer Center experience. Cancer 96:174-180
87. Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA 2001 Intra-operative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg 136:1020-1025; discussion 1025-1026
88. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731
89. Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chili A 2001 Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 12:S51-S861
90. Warner RR, O'Dorisio TM 2002 Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin Nucl Med 32:79-83
91. Hoefnagel CA, den Hartog Jager FC, Taal BG, Abeling NG, Engelsman EE 1987 The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 13:187-191
92. 11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 27:33-41
93. Eriksson B, Bergström M, Lilja A, Ahlstrom H, Langstrom B, Oberg K 1993 Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol 32:189-196
94. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, Moser E, Nitzsche E 2001 Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 220: 373-380
95. Ahlström H, Eriksson B, Bergström M, Bjurling P, Langstrom B, Oberg K 1995 Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 195:333-337
96. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G 1998 Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79-83
97. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Itoh K, Imamura M, Konishi J 2000 Evaluation of pancreatic islet cell tumors by fluorine-18 fluorodeoxyglucose positron emission tomography: comparison with other modalities. Clin Nucl Med 25:115-119
98. Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ 2001 Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med 28:478-482
99. Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Fuger B, Li SR, Angelberger P, Raderer M, Wogritsch S, Kurtaran A, Kletter K, Dudczak R 2001 Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 12:S41-S45
100. Denham DW, Norman J 1998 Cost-effectiveness of preoperative sestamibi scan for primary hyperparathyroidism is dependent solely upon the surgeon's choice of operative procedure. J Am Coll Surg 186:293-305
101. Clark OH 1995 Surgical treatment of primary hyperparathyroidism. Adv Endocrinol Metab 6:1-16
102. Perrier ND, Ituarte PH, Morita E, Hamill T, Gielow R, Duh QY, Clark OH 2002 Parathyroid surgery: separating promise from reality. J Clin Endocrinol Metab 87:1024-1029
103. Giordano A, Rubello D, Casara D 2001 New trends in parathyroid scintigraphy. Eur J Nucl Med 28:1409-1420
104. Arkles LB 2002 Preoperative localization of parathyroid adenomas: the protagonist's view. Intern Med J 32:179-182
105. O'Doherty MJ, Kettle AG, Wells P, Collins RE, Coakley AJ 1992 Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med 33:313-318
106. Dijkstra B, Healy C, Kelly LM, McDermott EW, Hill AD, O'Higgins N 2002 Parathyroid localisation - current practice. J R Coll Surg Edinb 47:599-607
107. Norman J, Chheda H 1997 Minimally invasive parathyroidectomy facilitated by intraoperative nuclear mapping. Surgery 122:998-1003
108. Fraker DL 2000 Update on the management of parathyroid tumors. Curr Opin Oncol 12:41-48
109. Neumann DR, Esselstyn CB, MacIntyre WJ, Go RT, Obuchowski NA, Chen EQ, Licata AA 1996 Comparison of FDG-PET and sestamibi-SPECT in primary hyperparathyroidism. J Nucl Med 37:1809-1815
110. Melon P, Luxen A, Hamoir E, Meurisse M 1995 Fluorine-18- fluorodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Eur J Nucl Med 22:556-558
111. Sundin A, Johansson C, Hellman P, Bergstrom M, Ahlstrom H, Jacobson GB, Langstrom B, Rastad J 1996 PET and parathyroid L-[carbon-11]methionine accumulation in hyperparathyroidism. J Nucl Med 37:1766-1770
112. Neumann DR, Esselstyn Jr CB, MacIntyre WJ, Chen EQ, Go RT, Licata AA 1997 Regional body FDG-PET in postoperative recurrent hyperparathyroidism. J Comput Assist Tomogr 21:25-28
113. Hellman P, Ahlstrom H, Bergström M, Sundin A, Langstrom B, Westerberg G, Juhlin C, Akerstrom G, Rastad J 1994 Positron emission tomography with 11C-methionine in hyperparathyroidism. Surgery 116:974-981
114. 11C]Methionine positron emission tomography for patients with persistent or recurrent hyperparathyroidism after surgery. Eur J Endocrinol 139:195-197
115. Alexander Jr HR, Chen CC, Shawker T, Choyke P, Chan TJ, Chang R, Marx SJ 2002 Role of preoperative localization and intraoperative localization maneuvers including intraoperative PTH assay determination for patients with persistent or recurrent hyperparathyroidism. J Bone Miner Res 17(Suppl 2):N133-N140
116. Neumann DR, Esselstyn CB, Kim EY 1996 Recurrent postoperative parathyroid carcinoma: FDG-PET and sestamibi-SPECT findings. J Nucl Med 37:2000-2001
117. 18F]fluoro-ethyl-spiperone. Eur J Nucl Med 24:1149-1155
118. 11C]-L-deprenyl. Neurosurgery 30:855-861
119. 11C-N-methylspiperone. J Comput Assist Tomogr 10:175-178
120. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J 1996 Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 37:1428-1436
121. Turkington TG, Coleman RE 2002 Clinical oncologic positron emission tomography: an introduction. Semin Roentgenol 37:102-109
122. Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T, Phelps ME, Larson SM, Balatoni J, Finn R, Sadelain M, Tjuvajev J, Blasberg R 2000 Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2:118-138
123. Blasberg RG, Tjuvajev JG 1999 Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q J Nucl Med 43:163-169
124. Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R, Safer M, Beattie B, DiResta G, Daghighian F, Augensen F, Koutcher J, Zweit J, Humm J, Larson SM, Finn R, Blasberg R 1998 Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res 58:4333-4341
125. Sullivan DC, Hoffman JM 2001 In vivo imaging of gene expression. Semin Radiat Oncol 11:37-46
126. Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, Larson S, Sadelain M, Blasberg R, Gelovani Tjuvajev J 2001 Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci USA 98:9300-9305